- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study2020 | First Faculty of Medicine
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma2015 | First Faculty of Medicine
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial2022 | First Faculty of Medicine
- The role of elotuzumab in the treatment of multiple myeloma2021 | First Faculty of Medicine
- Elotuzumab in the treatment of multiple myeloma2020 | First Faculty of Medicine
- Morphology of anterior cingulate cortex and its relation to schizophrenia2023 | Third Faculty of Medicine
